STOCK TITAN

Vanguard amends Schedule 13G/A for Repligen (RGEN): reports 0 shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 7 to Schedule 13G/A reporting no beneficial ownership of Repligen Corp common stock. The filing states 0 shares beneficially owned, representing 0% of the class, and shows zero voting and dispositive power. The amendment notes an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report ownership separately.

The filing lists Vanguard’s principal office at 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.

Positive

  • None.

Negative

  • None.





759916109

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does Vanguard report for RGEN ownership in this Schedule 13G/A amendment?

The filing states 0 shares beneficially owned and 0% of the class. It also reports 0 voting and dispositive power as of the amendment's disclosure.

Why did The Vanguard Group change its reporting in the RGEN filing?

Vanguard cites an internal realignment on January 12, 2026 under SEC Release No. 34-39538, causing certain subsidiaries to report ownership separately from The Vanguard Group, Inc.

Who signed the RGEN Schedule 13G/A Amendment No. 7 for Vanguard?

The filing is signed by Ashley Grim, Head of Global Fund Administration, and dated 03/27/2026, representing Vanguard's attestation on the reported ownership.

Does the filing indicate Vanguard still controls shares for other accounts in RGEN?

The filing states Vanguard entities have rights over dividends or proceeds for managed accounts, but it reports no beneficial ownership for The Vanguard Group itself in this amendment.

Where is Vanguard’s principal business address listed in the RGEN amendment?

The Schedule 13G/A lists The Vanguard Group's principal office as 100 Vanguard Blvd., Malvern, PA, 19355 in the filing's contact information.
Repligen

NASDAQ:RGEN

View RGEN Stock Overview

RGEN Rankings

RGEN Latest News

RGEN Latest SEC Filings

RGEN Stock Data

6.45B
53.02M
Medical Instruments & Supplies
Biological Products, (no Diagnostic Substances)
Link
United States
WALTHAM